TB-500 Methionine Oxidation: The Thymosin Beta-4 Sulfoxide Degradant and What a COA Must Resolve

TB-500 carries a single methionine at position 6, and oxidising that one residue converts the peptide into thymosin beta-4 sulfoxide, a species with roughly 20-fold weaker actin binding and a completely different extracellular signalling profile. The sulfoxide is 16 Da heavier than the parent, elutes ahead of it on reversed-phase HPLC, and forms spontaneously in solution exposed to air. A certificate of analysis for TB-500 that does not resolve this pre-peak is reporting a purity number that may already include the degradant. Most discussion of thymosin beta-4 sulfoxide sits in the wound-healing literature, where it is treated as a biologically interesting metabolite. For a laboratory that receives a lyophilised vial, the same chemistry is a stability and analytical question, and it deserves to be handled that way.

Where the methionine sits and why it matters

Thymosin beta-4 is a 43-residue, N-terminally acetylated, intrinsically disordered peptide (Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES, monoisotopic mass around 4960 Da). TB-500 is the research designation for the synthetic peptide. Methionine-6 is the only methionine in the sequence and the only residue that oxidises readily under ambient conditions, since the sequence contains no cysteine, no tryptophan and no free N-terminal amine. That makes the oxidation profile of TB-500 unusually simple: there is effectively one primary oxidative degradant, and it is the Met6 sulfoxide.

Position 6 is not a neutral location. Huff, Zerzawy and Hannappel (European Journal of Biochemistry, 1995, 230:650-657) mapped the actin-binding determinants of beta-thymosins using equilibrium centrifugation, chemical cross-linking and viscometry. The apparent dissociation constant for thymosin beta-4 with bovine heart G-actin was 2.5 uM. Oxidation at Met6 to the sulfoxide, or deletion of the first six or twelve residues, raised the apparent dissociation constant to 38 to 53 uM. Removing the first 23 residues abolished binding altogether. The sulfoxide still inhibited salt-induced actin polymerisation, but only at a 20-fold higher concentration than the native peptide, and the truncated forms did not inhibit it at all. The first six residues, with methionine at their C-terminal end, are indispensable to the polymerisation-inhibiting function that defines the peptide.

Heintz and colleagues (European Journal of Biochemistry, 1994, 223:345-350) reached the same number from a different direction. Working with thymosin beta-4 purified from bovine lung, they found the peptide was accompanied by a derivative in which Met6 was replaced by its sulfoxide. That derivative inhibited actin polymerisation approximately 20 times less effectively than the parent, and the loss tracked a 20-fold lower affinity for actin under polymerising conditions. An equimolar amount of native thymosin beta-4 prevented polymerisation almost completely; the same amount of sulfoxide allowed polymerisation to proceed much as it does for pure actin. The authors noted that the sulfoxide in their preparations was presumably a product of autoxidation, which is the point a research buyer should take from the paper: the degradant appears during isolation and handling, not only in biology.

The sulfoxide is not inert

What makes TB-500 unusual among oxidation-prone peptides is that the degradant is not simply a weaker version of the parent. Young and colleagues (Nature Medicine, 1999, 5:1424-1427) showed that monocytes cultured with glucocorticoids release thymosin beta-4 sulfoxide, and that the oxidised peptide inhibits neutrophil chemotaxis in vitro. In a mouse paw oedema model, the oxidised peptide, but not the native form, was a potent inhibitor of carrageenin-induced swelling. The authors described this as oxidation attenuating the intracellular G-actin sequestering activity while greatly enhancing extracellular signalling. In other words, Met6 oxidation switches the peptide from one function to another rather than switching it off.

Evans and colleagues (Nature Communications, 2013, 4:2081, open access) extended this with quantitative mass spectrometry. In zebrafish larvae, QTOF-MS on trypsin-digested tail fin tissue showed the sulfoxide fraction of total thymosin beta-4 rising from 2.0 percent (plus or minus 1.4 percent SEM) to 10.4 percent (plus or minus 1.96 percent SEM) one hour after wounding, a roughly 5-fold increase (n=100 wounded fins per condition, three replicates, p of 0.01 or less). Pre-incubation with the hydrogen peroxide inhibitor diphenyleneiodonium cut the rise to 6.4 percent, placing the oxidation downstream of wound-derived peroxide. Latex beads pre-adsorbed with synthetic sulfoxide and implanted into the flank reduced macrophage counts within 500 micrometres from 20 (plus or minus 4.65) to 8.25 (plus or minus 2.39) at three hours (n=5 fish per condition, p of 0.01 or less).

The mouse data in the same paper matter for a different reason. In hearts from mice given the parent peptide after coronary ligation, the oxidised fraction of thymosin beta-4 rose from 4.7 percent (plus or minus 1.3 percent) in sham controls to 66 percent (plus or minus 5.1 percent) at day 2 and stayed at 68.6 percent (plus or minus 9.3 percent) through day 28 (n=4, repeated measures ANOVA, p of 0.001 or less). Infarct volume by late gadolinium enhancement MRI at day 28 was 43.3 microlitres (plus or minus 4.9) in vehicle controls versus 22.0 microlitres (plus or minus 5.3) in the peptide group (n=5 versus n=4, p of 0.05 or less). In human CD14+ monocyte and CD4+ T-cell co-cultures, the sulfoxide reduced interferon-gamma release from 1830 to 1271.5 pg/mL (n=4, Wilcoxon matched-pairs, p of 0.05 or less) and cut monocyte adherence from 219,167 to 89,167 cells (n=3, p of 0.05 or less). The parent peptide is converted to the sulfoxide in oxidising tissue at high yield, and the sulfoxide then does its own signalling. Any in vivo or cell-culture result attributed to TB-500 is, in part, a result attributable to its oxidation product.

What this means for a purity chromatogram

Methionine sulfoxide formation adds one oxygen atom, a monoisotopic mass shift of 15.995 Da. On a deconvoluted electrospray spectrum of TB-500 this appears as a second species 16 Da above the parent. Because the sulfoxide sulfur is a new stereocentre, the oxidised peptide exists as two diastereomers that can partially separate on a high-resolution reversed-phase gradient, so the pre-peak is sometimes a doublet. Oxidation also increases polarity, which is why the sulfoxide elutes earlier than the parent on C18. This is well enough characterised that Urso and colleagues (Analytical Biochemistry, 2010, 402:13-19) used the oxidised form of thymosin beta-4 as the internal standard for a label-free MALDI-TOF quantification of the native peptide in cerebrospinal fluid, relying on the fact that the two are cleanly resolved by mass while behaving almost identically in every other respect.

The analytical consequence follows directly. Thymosin beta-4 and its Met6 sulfoxide are 43-residue peptides differing by a single oxygen. On a short, steep reversed-phase gradient of the kind used for a rapid purity screen, the two peaks can merge, and an area-percent purity figure will then count the sulfoxide as parent. On a shallow gradient with adequate resolution, the sulfoxide appears as a distinct earlier peak and is subtracted from purity. Two certificates reading 98 percent can therefore describe materially different vials, one where the sulfoxide was resolved and excluded and one where it was not. The gradient conditions and the presence or absence of a pre-peak are the details to read, not the headline number. The oxytocin degradation article on this site makes the same argument for a disulfide peptide, where the degradants are trisulfide and tetrasulfide species rather than a sulfoxide: the compendial methods for that peptide have no published stability-indicating status, and the same question should be asked of any TB-500 method.

Cabras and colleagues (Expert Opinion on Biological Therapy, 2015, 15 Suppl 1:S191-S201) used HPLC coupled to high-resolution LTQ-Orbitrap mass spectrometry to characterise thymosin beta-4 proteoforms in tissues and body fluids, and the sulfoxide derivatives of both thymosin beta-4 and beta-10 were among the modifications identified, alongside C-terminally truncated forms and lysine-acetylated variants. High-resolution mass spectrometry finds these species readily. The question for a research buyer is whether the certificate they receive was generated with a method that would.

What a TB-500 certificate of analysis should show

Identity by mass, not only by retention time

An identity test that reports only an observed molecular mass matching the theoretical value confirms that the parent is present. It does not confirm that the sulfoxide is absent. A useful identity section reports the deconvoluted spectrum, or at minimum the multiply charged ions, so that a plus-16 species can be seen or ruled out. Since methionine oxidation is the single dominant chemical degradation route for this sequence, a certificate that reports oxidised species as a named impurity is far more informative than one reporting a bare purity percentage. Every Maple Research Labs batch certificate is linked from the product page, and the TB-500 product listing carries the current batch report for the vial being supplied.

A gradient that resolves the pre-peak

Purity chromatograms should state the column, gradient and detection wavelength. A run of 30 minutes or longer with a shallow acetonitrile ramp is the norm for resolving closely related peptide impurities; a five-minute screen is not. If a certificate shows a small peak immediately ahead of the main peak, that is consistent with the sulfoxide and the area should already be excluded from the purity figure. If the chromatogram shows a single symmetrical peak on a fast gradient, the absence of a pre-peak is not evidence that the sulfoxide is absent. The general logic of interpreting impurity peaks, and the thresholds at which they must be reported, is covered in the peptide degradation pathways article, which treats methionine oxidation in general terms; this article is the TB-500-specific case.

Storage and handling notes that match the chemistry

Methionine oxidation requires an oxidant. In a sealed lyophilised vial the available oxidants are headspace oxygen, trace peroxide in any excipient, and transition-metal traces that catalyse oxygen activation. Once the vial is reconstituted, dissolved oxygen and light-driven radical formation are added to the list. This is why the primary TB-500 article on this site notes that the disordered structure makes the peptide susceptible to oxidation in solution, and why lyophilised storage under desiccation at minus 20 degrees Celsius is standard practice. Reconstituted solutions held at 2 to 8 degrees Celsius should be used within a short window and, where methionine-containing peptides are concerned, prepared in degassed or nitrogen-purged solvent. The TB-500 research overview covers the receptor-level pharmacology, the ILK pathway and the Ac-SDKP tetrapeptide, which is the other well-characterised thymosin beta-4 derivative and arises by enzymatic cleavage rather than oxidation.

An experimental design point that follows from the biology

Because the sulfoxide has its own activity, a partially oxidised vial does not just deliver less active peptide. It delivers a mixture of two agents with different mechanisms: an actin-sequestering peptide and an anti-inflammatory signalling peptide with 20-fold weaker actin affinity. In a wound-closure or cardiac model where the readout is inflammatory cell infiltration, an oxidised preparation may perform differently from a fresh one, and the difference will not be a simple loss of effect. Evans and colleagues addressed this deliberately by running the parent and the synthetic sulfoxide as separate arms and by measuring the oxidised fraction in tissue by mass spectrometry. A laboratory that cannot do that in-house has one substitute: a certificate that states how much sulfoxide was in the vial on the day of release, and a storage record that limits how much has formed since.

For comparison, a peptide where oxidation simply reduces potency creates a quantitative error. A peptide where oxidation creates a second active species creates a qualitative one, and the two cannot be separated after the fact from the biological readout alone. That is the specific reason Met6 oxidation deserves more attention in TB-500 studies than methionine oxidation receives in most other research peptides. The broader case for batch-specific reporting, and what a certificate should contain in general, is set out on the certificates of analysis page.

Key Research Findings

• Met6 oxidation raised the apparent dissociation constant of thymosin beta-4 for G-actin from 2.5 uM to 38 to 53 uM, and the sulfoxide inhibited actin polymerisation only at a 20-fold higher concentration than the parent (Huff, Zerzawy and Hannappel, European Journal of Biochemistry, 1995, 230:650-657).
• Thymosin beta-4 sulfoxide was found alongside the parent in bovine lung preparations, inhibited actin polymerisation approximately 20 times less effectively, and was presumed to arise by autoxidation during isolation (Heintz et al., European Journal of Biochemistry, 1994, 223:345-350).
• Monocytes cultured with glucocorticoids release thymosin beta-4 sulfoxide; the oxidised peptide inhibited neutrophil chemotaxis in vitro and carrageenin-induced paw oedema in mice, while the native peptide did not (Young et al., Nature Medicine, 1999, 5:1424-1427).
• In wounded zebrafish tail fin, the sulfoxide fraction rose from 2.0 to 10.4 percent of total thymosin beta-4 within one hour (n=100 fins per condition, p of 0.01 or less), and in mouse hearts after coronary ligation the oxidised fraction rose from 4.7 to 66 percent by day 2 (n=4, p of 0.001 or less) (Evans et al., Nature Communications, 2013, 4:2081).
• In the same study, the sulfoxide reduced interferon-gamma release in human monocyte and T-cell co-culture from 1830 to 1271.5 pg/mL (n=4, p of 0.05 or less) and cut monocyte adherence from 219,167 to 89,167 cells (n=3, p of 0.05 or less).
• The oxidised peptide is 15.995 Da heavier than the parent and is cleanly resolved by mass, which allowed it to serve as the internal standard for label-free MALDI-TOF quantification of native thymosin beta-4 in cerebrospinal fluid (Urso et al., Analytical Biochemistry, 2010, 402:13-19).
• Sulfoxide derivatives of both thymosin beta-4 and beta-10 were identified in tissues and body fluids by HPLC coupled to high-resolution Orbitrap mass spectrometry (Cabras et al., Expert Opinion on Biological Therapy, 2015, 15 Suppl 1:S191-S201).

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use. All products supplied by Maple Research Labs are intended for in vitro research and laboratory use by qualified researchers.